In an A431 xenograft tumor model, Hermiston and coworkers were able to show significant inhibition of tumor growth when the anti-EGFR antibody-expressing AAV1 was administered intramuscularly in both prophylactic and therapeutic settings [69]. Here, EGFR is linked to neoplasm.